Cargando…

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism

BACKGROUND: Hypoparathyroidism is a rare disease characterized by deficiency of parathyroid hormone (PTH), resulting in abnormal mineral homeostasis. Conventional therapy (active vitamin D and calcium) targets short-term symptoms, but fails to restore normal PTH physiology, and may lead to complicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Intekhab, Eriksen, Erik, Hofbauer, Lorenz, Khan, Aliya, Le, John, Marcocci, Claudio, Markova, Denka, Pagotto, Uberto, Palermo, Andrea, Pihl, Susanne, Rejnmark, Lars, Schwarz, Peter, Shu, Aimee, Sibley, Christopher, Vansaghi, Lisa, Vokes, Tamara, Clarke, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Bone & Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625017/ http://dx.doi.org/10.1210/jendso/bvac150.398

Ejemplares similares

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism
por: Clarke, Bart L, et al.
Publicado: (2020)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
por: Bilezikian, John, et al.
Publicado: (2019)

SAT-408 Bioactivity of Long Acting PTH Fusion Molecules Tested in a Novel Non-Surgical Animal Model of Hypoparathyroidism
por: Wilkinson, Ian R, et al.
Publicado: (2020)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

ODP118 PTH (1-34) Replacement Therapy for Hypoparathyroidism due to Sporadic Calcium Sensing Receptor Gain-of-Function Point Mutation
por: Basina, Marina, et al.
Publicado: (2022)

MON-523 Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

SAT237 AZP-3601, A Novel PTH 1 Receptor Agonist, Induces Rapid Reduction And Normalization Of Urinary Calcium In Chronic Hypoparathyroid Patients
por: Figueres, Lucile, et al.
Publicado: (2023)

OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial
por: Kamenicky, Peter, et al.
Publicado: (2023)

MON-LB091 An Overview of the Etiology, Clinical Manifestations, Management Strategies, and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry
por: Alalawi, Yousef, et al.
Publicado: (2019)

MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism
por: Saponaro, Federica, et al.
Publicado: (2020)

MON-524 Risk of Decline in Estimated Glomerular Filtration Rate (eGFR) in Patients with Chronic Hypoparathyroidism (HypoPT)
por: Chen, Kristina, et al.
Publicado: (2019)

Delayed Diagnosis of Congenital Hypoparathyroidism in a Kindred of Three Patients With Autosomal Dominant Deafness
por: Dandurand, Karel, et al.
Publicado: (2021)

SAT233 Clinical And Economic Burden Of Postsurgical Chronic Hypoparathyroidism: A US Medicare Retrospective Analysis
por: Noori, Wahidullah, et al.
Publicado: (2023)

PSAT201 Hypoparathyroidism (HypoPT) in 16 Pregnancies in 7 Patients: A Case Series of Maternal and Neonatal Outcomes
por: Ali, Dalal S, et al.
Publicado: (2022)

OR07-01 Identification of the First Case of Acquired Autoimmune Parathyroid Hormone (PTH) Resistance Due to PTH1 Receptor (PTH1R) Autoantibodies
por: Mandl, Adel, et al.
Publicado: (2020)

MON-530 Hypoparathyroidism in Sweden
por: Kamal, Wafa, et al.
Publicado: (2019)

SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study
por: Mazoni, Laura, et al.
Publicado: (2020)

MON-533 Irisin in Post-Menopausal Women with Primary Hyperparathyroidism: An Interplay between Irisin and Pth
por: Palermo, Andrea, et al.
Publicado: (2019)

MON-527 Cardiovascular Autonomic Neuropathy As A Cause Of Quality Of Life Impairment In Subjects With Chronic Hypoparathyroidism.
por: Tabacco, Gaia, et al.
Publicado: (2019)

PSAT216 Turner Syndrome and Congenital Hypoparathyroidism
por: Jovanovic, Filip, et al.
Publicado: (2022)

FRI698 Hypoparathyroidism Secondary To Covid-19
por: Hussain, Mariam, et al.
Publicado: (2023)

Improving the Accuracy and Reliability of Parathyroid Hormone Levels Through the Mass-Spectrometric Measurement of Full-length PTH and C-Terminal PTH Fragments
por: Ulmer, Candice Z, et al.
Publicado: (2021)

PSAT209 A Remission of Hypocalcemia in Idiopathic Hypoparathyroidism
por: Puzio, Helene, et al.
Publicado: (2022)

SAT234 Variations In Clinical Practice Patterns For Hypoparathyroidism
por: Deering, Kathleen L, et al.
Publicado: (2023)

MON-538 Ca(2+)Allostery in PTH-Receptor Signaling
por: White, Alex, et al.
Publicado: (2019)

Ectopic Intact PTH Secretion Causing Humoral Hypercalcemia of Malignancy
por: Rauf, Mohammad Talha, et al.
Publicado: (2021)

PTH Protects Osteocytes From Oxidative Stress and Cellular Senescence
por: Uda, Yuhei, et al.
Publicado: (2021)

SUN-519 Hypoparathyroidism after Harvoni Treatment for Hepatitis C
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SUN-516 Fahr's Syndrome: A Rare Sequela of Hypoparathyroidism
por: Min, Lei Lei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_et0hk9ab6mt8f21lk2c363d9o3